Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Jazz Pharmaceuticals plc

Teva vs. Jazz: A Decade of Revenue Cost Dynamics

__timestampJazz Pharmaceuticals plcTeva Pharmaceutical Industries Limited
Wednesday, January 1, 20141174180009216000000
Thursday, January 1, 20151025260008296000000
Friday, January 1, 201610538600010044000000
Sunday, January 1, 201711018800011560000000
Monday, January 1, 201812154400010558000000
Tuesday, January 1, 20191279300009351000000
Wednesday, January 1, 20201489170008933000000
Friday, January 1, 20214407600008284000000
Saturday, January 1, 20225405170007952000000
Sunday, January 1, 20234355770008200000000
Monday, January 1, 20248480000000
Loading chart...

Infusing magic into the data realm

Analyzing Cost of Revenue: A Tale of Two Pharmaceutical Giants

In the ever-evolving pharmaceutical industry, understanding the cost of revenue is crucial for assessing a company's financial health. This analysis focuses on two major players: Teva Pharmaceutical Industries Limited and Jazz Pharmaceuticals plc, from 2014 to 2023.

Teva, a global leader in generic medicines, has consistently maintained a high cost of revenue, peaking in 2017 with a staggering 11.56 billion. However, a downward trend is evident, with a 31% decrease by 2022. In contrast, Jazz Pharmaceuticals, known for its innovative therapies, shows a more dynamic trajectory. Starting at 117 million in 2014, Jazz's cost of revenue surged by 360% to 540 million in 2022, reflecting its aggressive growth strategy.

This comparative analysis highlights the strategic differences between these companies, offering insights into their operational efficiencies and market positioning.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025